Our Pricing

Wegovy In Stock UK - All Doses Available Now

Published on: June 03, 2026

Searching for wegovy in stock uk all doses? Cured Pharmacy maintains full availability across all Wegovy dose strengths, from the 0.25mg starter pen through to the 2.4mg maintenance dose. Our UK-registered clinical team provides free online consultations, with genuine MHRA-licensed semaglutide pens dispatched discreetly to your door.

Why Wegovy Stock Shortages Have Affected UK Patients

Since its UK launch, Wegovy has experienced intermittent supply constraints due to unprecedented global demand for semaglutide-based weight loss treatments [1]. Many UK pharmacies have struggled to maintain consistent stock across all five dose strengths, particularly the higher maintenance doses that patients require for sustained weight management.

At Cured Pharmacy, we work directly with licensed UK wholesalers and maintain strategic stock reserves to ensure patients can access their prescribed dose without treatment interruption. Our superintendent pharmacist Tarun Kumar has implemented robust supply chain protocols specifically to address the availability challenges that have affected other providers.

The MHRA continues to monitor semaglutide supply across the UK, and we maintain transparent communication with patients about stock status. Unlike some providers who accept orders they cannot fulfil, we only offer doses that are genuinely available for immediate dispatch.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone in your digestive system [2]. When injected once weekly, semaglutide slows gastric emptying, reduces appetite signals to the brain, and enhances feelings of satiety after smaller meals.

In the landmark STEP 1 clinical trial, patients using Wegovy alongside lifestyle modifications achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [2]. These results represent some of the most significant weight loss outcomes seen in pharmaceutical trials for obesity treatment.

The medication works best when combined with a reduced-calorie diet and increased physical activity. Your UK prescriber will assess whether semaglutide is appropriate based on your BMI, medical history, and weight management goals during your free online consultation.

The Wegovy Dosing Schedule Explained

Wegovy follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst your body adjusts to semaglutide [1]. Treatment begins with 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose.

This stepped approach significantly reduces the nausea and digestive discomfort that some patients experience when starting GLP-1 treatments. Clinical trials demonstrated that gradual titration improved treatment adherence and reduced discontinuation rates compared to faster escalation schedules [2].

Wegovy vs Mounjaro: Comparing UK Weight Loss Injections

Both Wegovy and Mounjaro are once-weekly injectable treatments licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related health conditions. However, they work through different mechanisms that produce distinct clinical outcomes.

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates two separate hormone pathways simultaneously [3]. This dual action has demonstrated superior weight loss results in head-to-head trials, with tirzepatide producing an average 22.5% body weight reduction compared to 14.9% with semaglutide in comparable study populations [3][2].

The choice between these medications depends on individual factors including your medical history, previous treatment responses, budget considerations, and prescriber recommendation. Some patients may start with one medication and switch to another if they experience tolerability issues or suboptimal results.

Side Effect Profiles and Tolerability

Both semaglutide and tirzepatide share similar side effect profiles, with gastrointestinal symptoms being most common during the initial dose escalation phases [1][3]. Nausea, diarrhoea, constipation, and abdominal discomfort typically diminish as your body adapts to treatment over 4-8 weeks.

Clinical trials showed that approximately 5-7% of patients discontinued Wegovy due to adverse effects, most commonly gastrointestinal symptoms [2]. Your prescriber will review your complete medical history to identify any contraindications and provide guidance on managing potential side effects throughout your treatment journey.

Wegovy Pricing and UK Prescription Requirements

Wegovy is available at Cured Pharmacy with transparent upfront pricing displayed before you begin your clinical consultation. As a prescription-only medication regulated by the MHRA, Wegovy requires assessment by a UK-registered prescriber who will evaluate your suitability based on clinical guidelines.

Our free online consultation takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. The assessment is reviewed by our UK clinical team, typically within 24 hours on weekdays, and your prescription is issued electronically if treatment is deemed appropriate.

We provide genuine UK-licensed Wegovy pens sourced exclusively from MHRA-approved wholesalers. Every pen includes the manufacturer's patient information leaflet, dosing instructions, and needle safety guidance. Our pharmacy team is available by phone during business hours if you have questions about injection technique or storage requirements.

What Your Wegovy Prescription Includes

Each Wegovy prescription covers a four-week supply of your current dose strength, delivered in a single pre-filled injection pen. The pen contains four individual doses, with each weekly injection administered subcutaneously in your abdomen, thigh, or upper arm.

Your first prescription will include the 0.25mg starter dose unless your prescriber determines a different starting point is appropriate based on previous semaglutide exposure. Subsequent prescriptions follow the standard escalation schedule, with dose increases occurring monthly until you reach the 2.4mg maintenance dose.

Clinical Evidence Supporting Wegovy for Weight Management

The STEP clinical trial programme represents the most comprehensive evaluation of semaglutide for weight management, enrolling over 4,500 participants across multiple international sites [2]. These randomised, double-blind, placebo-controlled trials demonstrated consistent and clinically significant weight loss across diverse patient populations.

STEP 1, the pivotal trial supporting UK regulatory approval, showed that 86.4% of participants on Wegovy achieved at least 5% body weight loss, compared to 31.5% in the placebo group [2]. Furthermore, 69.1% achieved at least 10% weight loss, and 50.5% achieved at least 15% weight loss over 68 weeks of treatment.

Long-term extension studies have confirmed that weight loss is maintained with continued treatment, whilst discontinuation typically results in gradual weight regain [4]. This underscores the importance of viewing semaglutide as part of a comprehensive, long-term weight management strategy rather than a short-term intervention.

The STEP trials also demonstrated improvements in cardiovascular risk markers including blood pressure, lipid profiles, and glycaemic control in participants without diabetes [2]. These metabolic benefits contribute to the overall health improvements associated with clinically significant weight loss.

Starting Your Wegovy Treatment Journey at Cured Pharmacy

Beginning treatment with Wegovy involves a straightforward process designed to ensure clinical safety whilst minimising administrative barriers. Your journey starts with our free online consultation, accessible 24/7 through our secure platform, where you'll answer questions about your health history and weight management goals.

Our UK-registered prescribers review every consultation individually, applying NICE guidelines and MHRA prescribing criteria to determine suitability. If approved, your prescription is issued electronically and sent directly to our dispensing team. We dispatch orders Monday through Friday, with discreet packaging that reveals no indication of contents.

Once you begin treatment, you'll follow the standard Wegovy dose escalation schedule, with monthly increases until reaching the 2.4mg maintenance dose. Our clinical team remains available throughout your treatment for questions about side effects, injection technique, or dose adjustments. Regular follow-up consultations ensure ongoing prescriber oversight as required by UK regulations.

We recommend coordinating with your NHS GP regarding your private weight loss treatment, particularly if you have existing health conditions or take other medications. Your GP can provide complementary support including dietary counselling, exercise guidance, and monitoring of relevant health markers throughout your weight loss journey.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.